Longeveron initiated with a Buy at Roth MKM
Roth MKM last night initiated coverage of Longeveron (LGVN) with a Buy rating and $10 price target The firm says its investment thesis is driven by the 100% transplant-free survival benefits at the end of five years delivered by Lomecel-B in hypoplastic left heart syndrome.
We recently compiled a list of the 11 AI News You Should Not Miss. In this article, we are going to take a look at where ...
Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company has reported ...
Yext (NYSE:YEXT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Roth Mkm in a report released on Tuesday,Benzinga reports. They presently have a $10.50 target ...
Roth MKM last night initiated coverage of Entrada Therapeutics (TRDA) with a Buy rating and $29 price target Entrada is an ...
Roth MKM analyst Boobalan Pachaiyappan last night initiated coverage of Gain Therapeutics (GANX) with a Buy rating and $7 price target The firm says GT-02287, a potential $4B drug that ...
Roth Capital upgraded shares of Monogram Orthopaedics (NASDAQ:MGRM – Free Report) to a strong-buy rating in a research report report published on Monday,Zacks.com reports. Roth Capital also issued ...
Days after investment bank Roth MKM upgraded its rating on the Tesla Inc. TSLA stock from “neutral” to “buy,” other analysts have hiked price targets. What Happened: Bank of America ...
As of December 3, 2024, the average one-year price target for Longeveron is $8.67/share. The forecasts range from a low of $6.06 to a high of $10.50. The average price target represents an ...
Shares of Inseego (NASDAQ:INSG) moved higher in premarket trading on Thursday as Roth MKM raised its rating on the SaaS solutions provider to Buy and raised its price target on the stock to $15 ...
Roth MKM analyst Philip Shen maintained a Buy rating on Sunnova Energy International (NOVA – Research Report) today and set a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback